Against three versions of the Beta variant, the vaccine-elicited neutralising antibodies reduced six-to-eight fold compared to those produced against the original strain, while modest 3.2 to 2.1 fold reductions were seen for lineages of the variant first identified in India, including Delta and Kappa.
“These new data are encouraging and reinforce our belief that the Moderna Covid-19 vaccine should remain protective against newly detected variants,” CEO Stéphane Bancel said.
Earlier in the day, India granted permission to drugmaker Cipla Ltd to import Moderna's vaccine to the country for restricted use.
The drugmaker's shares were up 5.5% at $235.39 (about R3,366) in midday trading.
Moderna has submitted the data as a preprint to the website bioRxiv before peer review.